Better aligning diagnostic and drug review processes should be one key focus of upcoming user fee negotiations, says Amy Miller.
Miller is the executive VP of the Personalized Medicine Coalition (PMC), which includes members from the diagnostics and drug industries, as well as the medical, research and financial communities